San Francisco, 6 December 2018: The global radiodermatitis market is expected to
reach USD 442.1 million by 2025, according to a new report by Grand View
Research, Inc. The global radiodermatitis market is expected to grow at an
unprecedented rate owing to the growing prevalence of cancer patients
undergoing radiation therapy. The demand for radiodermatitis treatment is also
accentuated by unmet medical needs of consumers in emerging as well as
developed regions. Increasing focus of government healthcare organizations for
promoting awareness about available treatment products for radiodermatitisis
predicted to present the market with high potential growth opportunities.
In addition, increasing R&D activities
in the area of life sciences is presumed to be one of the significant factors
contributing toward growth of this market. For instance, in December 2016,
Mölnlycke Health Care AB entered into a licensing agreement with a Texas-based
R&D company Rochal Industries. This agreement was carried out to reinforce
its position as a prevention solutions firm. In addition, they have signed a
joint agreement to enhance their R&D capabilities and commercialize new
patented technological platforms.Other factors such as escalating number of
product launches with respect to radiodermatitis treatment and increasing
demand for these products are expected to boost the overall market growth.
Access
Research Report of Radiodermatitis Market@
www.grandviewresearch.com/industry-analysis/radiodermatitis-market
Further key findings from the report suggest:
· Topical products captured the largest share
in the product segment in 2016. The dominant share is attributable to ease in
availability, greater convenience, and superiority over oral products
· Topical products are also anticipated to
grow at an exponential rate owing to their availability in various formulations
such as creams, gels, and ointments according to the requirement of the patient
· In 2016, retail pharmacy accounted for the
substantial share of the distribution channel segment as a consequence of ease
in availability and high convenience associated with it.
· Asia Pacific held the largest share of the
radiodermatitis market owing to presence of a large cancer patient base present
across this region
· North America held the secondlargest share
owing to extensive R&D activities that have fueled high potential growth
opportunities
· In addition, availability of
therapeutically advanced products across North America is one of the major
factors contributing toward itshighshare
· The competition is marked by major players
undertaking strategies such as product launches, distribution agreements, and
strategic collaborations that haveled to significant growth in their respective
market share
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global radiodermatitis market on the basis of product, distribution channel,
and region:
Radiodermatitis Product Outlook (Revenue,
USD Million, 2014 - 2025)
·
Topical
·
Oral
·
Dressings
Radiodermatitis Distribution Channel Outlook (Revenue,
USD Million, 2014 - 2025)
·
Hospital Pharmacy
·
Retail Pharmacy
·
Online Pharmacies
Radiodermatitis Regional Outlook (Revenue,
USD Million, 2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Access Press Release of
Radiodermatitis Market@ www.grandviewresearch.com/press-release/global-radiodermatitis-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
No comments:
Post a Comment